Why the study?
The effects of glucagon-like peptide-1 receptor agonists on major coronary events, including myocardial infarction, unstable angina, and coronary revascularization, in patients with type 2 diabetes mellitus required assessment.
Do GLP-1RAs reduce major coronary events in high-risk patients with type 2 diabetes mellitus?
Comparison
GLP-1RAs vs placebo
Design
Meta-analysis of studies with a cardiovascular endpoint
Key result
GLP-1RA treatment reduced fatal and nonfatal myocardial infarction by 8% (OR 0.92; 95% CI 0.86-0.99; P=0.02) compared to placebo in patients with type 2 diabetes.
Authors
Loading...
GLP-1RAs merit priority for MI prevention in high-risk T2DM; reinforces RCT-level coronary protection in meta-analysis.
Meta-Analysis (n=64,236)
Do GLP-1RAs reduce major coronary events in high-risk patients with type 2 diabetes mellitus?
Odds Ratio: 0.92 (95% CI 0.86–0.99)
p-value: p=0.02
In high-risk patients with T2DM, GLP-1RAs significantly reduce the risk of fatal and nonfatal myocardial infarction, particularly with human-based and once-weekly formulations.
Guo et al. (2023) conducted a meta-analysis in type 2 diabetes mellitus (n=64,236). glucagon-like peptide-1 receptor agonists (GLP-1RAs) vs. placebo was evaluated on fatal and nonfatal MI (OR 0.92, 95% CI 0.86-0.99, p=0.02). GLP-1RA treatment reduced fatal and nonfatal myocardial infarction by 8% (OR 0.92; 95% CI 0.86-0.99; P=0.02) compared to placebo in patients with type 2 diabetes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: